The global Parkinsons Disease (PD) Drugs market size is predicted to grow from US$ 6083 million in 2025 to US$ 7904 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Most people with Parkinsons disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.

Infinity Market Research newest research report, the Parkinsons Disease (PD) Drugs Industry Forecast looks at past sales and reviews total world Parkinsons Disease (PD) Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Parkinsons Disease (PD) Drugs sales for 2025 through 2031. With Parkinsons Disease (PD) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Parkinsons Disease (PD) Drugs industry.

This Insight Report provides a comprehensive analysis of the global Parkinsons Disease (PD) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Parkinsons Disease (PD) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Parkinsons Disease (PD) Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Parkinsons Disease (PD) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Parkinsons Disease (PD) Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Parkinsons Disease (PD) Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Dopamine Agonist
    Monoamine Oxidase Inhibitors
    Acetylcholinesterase Inhibitors
    Glutamate Inhibitors

Segmentation by Application:

    Hospital
    Family

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Boehringer Ingelheim
    GlaxoSmithKline
    Novartis
    Teva Pharmaceutical Industries
    AbbVie
    Abital Pharma
    Addex Therapeutics
    Biogen
    Eisai
    Eli Lilly
    F. Hoffmann-La Roche
    H. Lundbeck
    Impax Laboratories
    Kyowa Hakko Kirin
    Otsuka Pharmaceutical
    Pfizer

Key Questions Addressed in this Report

What is the 10-year outlook for the global Parkinsons Disease (PD) Drugs market?
What factors are driving Parkinsons Disease (PD) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Parkinsons Disease (PD) Drugs market opportunities vary by end market size?
How does Parkinsons Disease (PD) Drugs break out by Type, by Application?